Drug intelligence / Profile preview

ALF-202

Development stage: Phase 1
Lead developer: Beijing Allife Medicine Technology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

ALF-202 is an investigational cell therapy developed by Allife Medical Science and Technology Co., Ltd., comprising allogeneic endothelial progenitor cells (EPCs) derived from induced pluripotent stem cells (iPSCs). It is currently under investigation for its potential therapeutic benefits in acute ischemic stroke and severe lower limb ischemia. The therapy is designed to facilitate the repair of damaged vascular endothelium, promote angiogenesis (the formation of new blood vessels), and secrete various growth factors to support tissue regeneration and functional recovery in affected areas.

Other names: Allogeneic Endothelial Progenitor Cells (EPCs) Injection

Beyond the preview

Go deeper on ALF-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALF-202.

Explore the full profile